DermTech, Inc.

DermTech, Inc., trading under the ticker DMTK, is a precision dermatology company operating in the healthcare and diagnostics sector, focused on non-invasive genomic skin testing designed to detect conditions including melanoma without traditional biopsy procedures. The company filed a Form 10-Q with the Securities and Exchange Commission on November 13, 2017, bearing accession number 0001144204-17-058352, reflecting its status as a reporting company during that period. DermTech subsequently completed a business combination through a special purpose acquisition vehicle to consolidate its public market presence, with its shares listed on Nasdaq under DMTK. For full filing history, ownership data, and deal analytics on DermTech and hundreds of other SPAC-linked companies, sign up for a SpacDesk account at SpacDesk.com.